William Gerard

SV Health Investors thesis

Rondo Therapeutics is a biopharmaceutical company breaking new ground in cancer therapy. The company’s mission is to advance bispecific antibody therapies that address unmet needs in the treatment of solid tumors. Rondo is developing a new class of bispecific antibodies designed to harness the immune system to target and eliminate tumors with enhanced safety. Rondo Therapeutics is supported by Canaan Partners, Red Tree Venture Capital, Johnson & Johnson, SV Health Investors, and Novo Holdings. In addition to RNDO-564, the company’s pipeline includes immune-engaging bispecifics for a range of s

Sector and stage focus

• Series B: Health & Hospital Services, Digital Health, Health IT
• Series A: Health IT, Health & Hospital Services, Digital Health
• general: Boston / New England
• Seed: Health IT, Digital Health, Health & Hospital Services

Is William Gerard a fit for your round?

Upload your pitch deck and see whether William Gerard appears in your top 20 matches.